Novo Nordisk is trading 3.09% down at $45.73 after Deutsche Bank downgraded the shares to sell and cut its price target by 9%, citing heightened concerns after the stock’s steep decline.
- China’s acceptance of the oral Wegovy application is a positive regulatory milestone.
- Investors appear cautious as competition intensifies; major U.S. indexes are higher, indicating company-specific weakness rather than broad market pressure.